Longevity pharmacology: are we finally seeing clinical progression?

Madia Lozupone at the University of Bari Aldo Moro conducted a critical narrative review of longevity pharmacology literature from January 2000 through April 2026, searching PubMed, Scopus, and Web of Science. The review evaluates progress across six domains: senescence biology and frailty, autophagy and mitophagy modulation, metabolic and nutrient-sensing pathways, stem cell-based rejuvenation, natural product-based rejuvenation, and microbiome-targeted interventions. The central finding is that while mechanistic understanding of aging has advanced rapidly, clinical translation remains uncertain. Systemic chronic inflammation is identified as a central integrative driver of age-related disease, connecting multiple proposed interventions. The review also covers AI-enabled biomarker development as a tool for accelerating clinical trials. The author does not identify any single intervention that has demonstrated robust clinical efficacy for extending human healthspan. The perspective questions whether recent drug development announcements represent genuine clinical progression or incremental mechanistic findings being oversold. Natural product-based approaches (including NAD precursors, polyamines like spermidine, and polyphenols like resveratrol) are discussed alongside pharmaceutical approaches including rapamycin, senolytic combinations, and novel compounds.

Despite rapid scientific advances in longevity pharmacology, it remains uncertain whether this progress has translated into meaningful clinical outcomes.